| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam's Life Sciences District. This relocation is an expansion, which reflects Cytek's commitment to the EMEA region and highlights the company's ongoing investment in delivering world-class solutions, training, and support to researchers and clinicians worldwide.
The new site houses Cytek European offices and warehouse, which has increased the footprint by more than 40%, with a dedicated customer service and training center. The Training Center offers a fully functional lab environment, enabling researchers to receive hands-on training with Cytek instruments. This ensures scientists can maximize the potential of Cytek's Full Spectrum Profiling™ (FSP®) technology to unlock high-dimensional data and enable laboratories to achieve more with fewer resources.
The success of Cytek's reagent business is one of the major drivers of this expansion, signaling its importance to Cytek's global growth and innovation. As part of a strategic initiative to advance its reagent business, Cytek has transitioned warehouse operations in-house. This strengthens operational oversight, ensuring the highest standards of quality and control across the supply chain. The approach enhances organizational agility, improves operational efficiency, and accelerates turnaround times, delivering a consistent and dependable experience for customers.
"Europe has been a key region in Cytek's global growth journey, and we are making investments to strengthen our presence there," said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. "The new Amsterdam facility expands our capabilities across the EMEA region, enabling us to more efficiently deliver solutions and services that advance scientific understanding, accelerate data-driven decision-making, and foster innovation."
For more information, please visit https://cytekbio.com/.
Posted In: CTKB
